Molecular angiogenesis

Chemistry and Biology

Volumn 6, Issue 8, 1999, Pages

  Klagsbrun, Michael ^a,b   Moses, Marsha A ^b  

^a Department of Surgery ^*  (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0033179470     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(99)80081-7     Document Type: Review

References (70)

1. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
2. Isner, J.M. (1998). Angiogenesis. In Comprehensive Cardiovascular Medicine. (Topol, E.J., ed.) pp. 2973-3000, Lippencott-Raven, Philadelphia.
3. Hanahan, D. & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
4. Folkman, J. & D'Amore, P. (1996). Blood vessel formation: What is its molecular basis? Cell 87, 1153-1155.
5. Risau, W. (1997). Mechanisms of angiogenesis. Nature 386, 671-674.
6. Beck, L., Jr & D'Amore, P. (1997). Vascular development: Cellular and molecular regulation. FASEB J. 11, 365-373.
7. Asahara, T., et al., & Isner, J.M. (1997). Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.
8. Shi, Q., et al., & Hammond, W.P. (1998). Evidence for circulating bone marrow-derived endothelial cells. Blood 92, 362-367.
9. Takahashi, T. et al., & Asahara, T. (1999). Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 5, 434-438.
10. Moses, M.A. (1997). The regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells 15, 180-189.
11. 3 integrins during angiogenesis. Mol. Med. 4, 741-750.
12. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
13. Nguyen, M., Folkman, J. & Bischoff, J. (1992). 1-Deoxymannojirimycin inhibits capillary tube formation in vitro. Analysis of N-linked oligosaccharides in bovine capillary endothelial cells. J. Biol. Chem. 267, 26157-26165.
14. Benjamin, L.E., Hemo, I. & Keshet, E. (1998). A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591-1598.
15. Lindahl, P., Johansson, B.R., Leveen, P. & Betsholtz, C. (1997). Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277, 242-245.
16. Klagsbrun, M. & D'Amore, P. (1996). Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 7, 259-270.
17. Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22.
18. Dvorak, H.F., Nagy, J.A., Feng, D., Brown, L.F. & Dvorak, A.M. (1999). Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 97-132.
19. Ferrara, N. (1999). Vascular endothelial growth factor: Molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237, 1-30.
20. Korpelainen, E.I. & Alitalo, K. (1998). Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell. Biol. 10, 159-164.
21. De Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N. & Williams, LT. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-994.
22. Terman, B.I. et al., & Bohlen, P. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Comm. 187, 1579-1586.
23. Waltenberger, J., Claesson-Welch, L., Siegbahn, A., Shibuya, M. & Heldin, C-H. (1994). Different signal transduction properties of KDR and Flt-I, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988-26995.
24. Kaipainen, A., et al., & Alitalo, K. (1995). Expression of the fms-like tyrosine kinase Flt4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl Acad. Sci. USA 92, 3566-3570.
25. Soker, S., Takashima, S., Miao, H.Q., Neufeld, G. & Klagsbrun, M. (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745.
26. Adams, R.H., et al., & Klein, R. (1999). Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 13, 295-306.
27. Ferrara, N. et al., & Moore MW. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442.
28. Carmeliet, P. et al., & Nagy A. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
29. Shalaby, F., et al., & Schuh., A.C. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
30. Fong, G-H., Rossant, J., Gertsenstein, M. & Breitman, M.L. (1996). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-69.
31. Dumont, D.J., et al., & Alitalo K. (1998). Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282, 946-949.
32. Kitsukawa, T., et al., & Fujisawa, H. (1997). Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 19, 995-1005.
33. Shweiki, D., Itin, A., Neufeld, G., Gitay-Goren, H. & Keshet, E. (1993). Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J. Clin. Invest. 91, 2235-2243.
34. Shweiki, D., Itin, A., Soffer, D. & Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
35. Plate, K.H., Breler, G., Weich, H.A. & Risau, W. (1992). Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359, 845-848.
36. Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin, W.G., Jr & Goldberg, M.A. (1996). Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595-10599.
37. Dor, Y. & Keshet, E. (1997). Ischemia-driven angiogenesis. Trends Cardiovasc. Med. 7, 289-294.
38. Partanen, J. & Dumont, D.J. (1999). Functions of Tie1 and Tie2 receptor tyrosine kinases in vascular development. Curr. Top. Microbiol. Immunol. 237, 160-172.
39. Davis, S. & Yancopoulos, G.D. (1999). The angiopoietins: Yin and Yang in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 173-185.
40. Dumont, D.J., Fong, G.H., Puri, M.C., Gradwohl, G., Alitalo, K. & Breitman, M.L. (1995). Vasoularization of the mouse embryo: A study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev. Dyn. 203, 80-92.
41. Dumont, D.J., et al., & Breitman, M.L. (1994). Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8, 1897-1909.
42. Sato, T.N., et al., & Qin, Y. (1995). Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70-74.
43. Davis, S., et al. & Yancopoulos, G.D. (1996). Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87, 1161-1169.
44. Koblizek, T.I., Weiss, C., Yancopoulos, G.D., Deutsch, U. & Risau, W. (1998). Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. 8, 529-532.
45. Suri, C. et al., & Yancopoulos, G.D. (1998). Increased vascularization in mice overexpressing angiopoietin-1. Science 282, 468-471.
46. Vikkula, M. et al., & Olsen, B.R. (1996). Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87, 1181-1190.
47. Maisonpierre, P.C., et al., & Yancopoulos, G.D. (1997). Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60.
48. Klagsbrun, M. & D'Amore, P. (1991). Regulators of angiogenesis. Annu. Rev. Physiol. 53, 217-239.
49. Ingber, D., et al., & Folkman, J. (1990). Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557.
50. D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082-4085.
51. Rastinejad, F., Polverini, P.J. & Bouck, N.P. (1989). Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56, 345-355.
52. Dameron, K.M., Volpert, O.V., Tainsky, M.A. & Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584.
53. O'Reilly, M.S., et al., & Folkman, J. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
54. Holmgren, L., O'Reilly, M.S. & Folkman, J. (1995). Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1, 149-153.
55. Moser, T.L. et al., & Pizzo, S.V. (1999). Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl Acad. Sci. USA 96, 2811-2816.
56. O'Reilly, M.S. et al., & Folkman, J. (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
57. Dhanabal, M. et al., & Sukhatme, V.P. (1999). Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 274, 11721-11726.
58. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J. & Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812.
59. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M. (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
60. Moses, M.A., et al., & Langer, R. (1999). Troponin I is present in human cartilage and inhibits angiogenesis. Proc. Natl Acad. Sci. USA 96, 2645-2650.
61. Kim, K.J., et al., & Ferrara N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
62. Presta, L.G., et al., & Ferrara, N. (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599.
63. Adamis, A.P., et al., & Miller, J.W. (1996). Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114, 66-71.
64. Kendall, R.L., Wang, G. & Thomas, K.A. (1996). Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324-328.
65. Goldman, C.K., et al., & Cureiel, D.T. (1998). Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl Acad. Sci. USA 95, 8795-8800.
66. Aiello, L.P., et al., & Smith, L.E.H. (1995). Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble vegf-receptor chimeric proteins. Proc. Natl Acad. Sci. USA 92, 10457-10461.
67. Lin, P., Polverini, P., Dewhirst, M., Shan, S., Rao, P.S. & Peters, K. (1997). Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100, 2072-2078.
68. Fong, T.A., et al., & McMahon, G. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99-106.
69. Moses, M.A., Sudhalter, J. & Langer, R. (1990). Identification of an inhibitor of neovascularization from cartilage. Science 248, 1408-1410.
70. Brooks, P.C., Silletti, S., von Schalscha, T.L., Friedlander, M. & Cheresh, D.A. (1998). Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92, 391-400